In bladder cancer, METTL3 elevates the m6A level of CDCP1, enhancing its translation, which is modulated by YTHDF1, and the upregulation of METTL3 and CDCP1 is correlated with poor prognosis of bladder cancer 34. Here, METTL3 is linked to urinary bladder cancer.